The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Patent Protection - Rapid Blood Cell Separator

16 Mar 2011 07:00

RNS Number : 0188D
Akers Biosciences, Inc.
16 March 2011
 

Embargoed: 0700hrs, 16 March 2011

Akers Biosciences, Inc.

("ABI" or the "Company")

 

ABI Granted Patent Protection for Rapid Blood Cell Separator Technology

 

Akers Biosciences, Inc (AIM:AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, is pleased to announce that it has been granted patent protection in the United States, under patent 7,896,167 B2, for its novel blood cell separator technology (the "Technology"). The Technology forms a key element of the Company's PIFA POC test - the point-of-care extension of ABI's heparin platelet factor 4 rapid assay and has also been integrated into ABI's Lithium "Check" System. The Technology could also be used in many other diagnostic tests transforming them from use only in clinical laboratories to point-of-care.

 

ABI's Technology is for a novel composite which enables rapid blood cell separation of small volumes of whole blood, including those obtained from finger stick samples. Serum or plasma samples are extracted within minutes and are ready for immediate analysis by rapid assay devices, such as ABI's own products, delivering real-time results. By contrast, conventional methods of blood cell separation are labour-intensive and time consuming, typically involving blood collection and laboratory personnel as well as electrically-powered centrifuges and other specialised equipment.

 

Dr Raymond F. Akers, Jr., Executive Chairman, commented:

 

"With an industry shift towards point-of-care testing, ABI is well positioned as a provider of rapid diagnostic solutions that encompass the totality of the testing process, from sample preparation to test result. We believe that the Technology provides a significant step forward in the development of point-of-care diagnostic tests which could benefit not only ABI's products but those of the wider point-of-care diagnostic community."

 

Enquiries:

 

Thomas A. Nicolette, President and CEO

Dr Raymond F. Akers, Jr., Executive Chairman

Tel. +1 856 848 8698

Antony Legge or Noelle Greenaway

Daniel Stewart & Company plc (Nomad and Broker)

Tel. +44 (0)20 7776 6550

 

Ben Simons

M: Communications

Tel. +44 (0)20 7920 2340

 

About Akers Biosciences, Inc.

 

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical product distributors to maximise product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSFSFUIFFSESD
Date   Source Headline
8th May 20181:00 pmRNSHolding(s) in Company
27th Apr 20182:05 pmRNSSecond Price Monitoring Extn
27th Apr 20182:00 pmRNSPrice Monitoring Extension
26th Apr 20187:00 amRNSDirectorate Change
13th Apr 20185:45 pmRNSIssue of Equity
12th Apr 201812:00 pmRNSIndependent Sales Representative Agreements - PIFA
6th Apr 20184:30 pmRNSIssue of Equity
3rd Apr 201811:05 amRNSFinal Results
28th Mar 20184:20 pmRNSNotice of Fiscal Year 2017 Earnings - Rescheduled
26th Mar 20187:01 amRNSDistribution Agreement with Diagnostica Stago
26th Mar 20187:00 amRNSIssue of Equity
16th Mar 20184:00 pmRNSIssue of Equity
15th Mar 20185:30 pmRNSNotice of Results
9th Mar 20186:29 pmRNSIssue of Equity
2nd Mar 20185:15 pmRNSIssue of Equity
16th Feb 20185:45 pmRNSIssue of Equity
14th Feb 20185:30 pmRNSHoldings in Company
9th Feb 20186:00 pmRNSIssue of Equity
2nd Feb 20184:42 pmRNSIssue of Equity
26th Jan 20187:00 amRNSIssue of Equity
22nd Jan 20184:27 pmRNSHoldings in Company
19th Jan 20183:35 pmRNSIssue of Equity
16th Jan 20186:20 pmRNSIssue of Equity
15th Jan 20187:00 amRNSUpdate RE Admission of Shares
12th Jan 20187:00 amRNSIssue of Equity
5th Jan 20186:29 pmRNSIssue of Equity
4th Jan 20184:45 pmRNSHoldings in Company
27th Dec 20172:01 pmRNSIssue of Equity
22nd Dec 20177:00 amRNSClosing of Public Offering
19th Dec 20177:00 amRNSIssue of Equity
18th Dec 201711:00 amRNSForm S-1 Registration Statement - Amendment
15th Dec 201711:00 amRNSForm S-1 Registration Statement - Amendment
14th Dec 201711:00 amRNSForm S-1 Registration Statement - Amendment
11th Dec 201711:00 amRNSForm S-1 Registration Statement - Amendment
8th Dec 20173:30 pmRNSFurther IP Protection for Akers Wellness Line
1st Dec 20172:00 pmRNSForm 8K Filing
27th Nov 20177:00 amRNSForm S-1 Registration Statement
15th Nov 20177:00 amRNS3rd Quarter Results
14th Nov 20177:00 amRNSNew UK Channel for Rapid Alcohol Breathalyzer
13th Nov 20172:00 pmRNSNotice of Results
8th Nov 20171:59 pmRNSIssue of Equity
20th Oct 20177:00 amRNSPDMR Shareholding and Issue of Equity
19th Oct 20174:20 pmRNSDirector/PDMR Shareholding
13th Oct 20172:35 pmRNSWarrant Amendment and Exercise
7th Sep 20177:00 amRNSAppointment of U.S. VP of Sales & Distribution
15th Aug 20177:00 amRNSHalf-year Report
11th Aug 20177:00 amRNSIssue of Equity
8th Aug 20177:00 amRNSResult of AGM
3rd Aug 20174:30 pmRNSTrading Update and Notice of Q2 Results
20th Jul 201711:10 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.